Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003775 · ClinicalTrials.gov registry record · Phase 2
Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse
A Phase 2 study of Brain and Central Nervous System Tumors, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT00003775 is a Phase 2 study of Brain and Central Nervous System Tumors that has completed, run by Pfizer. The registered enrollment target is 60 participants, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00003775, a Phase 2 study of Brain and Central Nervous System Tumors, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic astrocytoma in first relapse.
Conditions Studied
Interventions
- DRUG leflunomide
Study Locations (20)
New York
- Cancer Center of Albany Medical Center - Albany
- Memorial Sloan-Kettering Cancer Center - New York
- New York Neurological Institute - New York
- Albert Einstein Comprehensive Cancer Center - The Bronx
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Henry Ford Hospital - Detroit
Ohio
- Barrett Cancer Center, The University Hospital - Cincinnati
- Arthur G. James Cancer Hospital - Ohio State University - Columbus
Arizona
- St. Joseph's Hospital and Medical Center - Phoenix
California
- USC/Norris Comprehensive Cancer Center - Los Angeles
Colorado
- University of Colorado Cancer Center - Denver
Florida
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 1998-12 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003775
The ClinicalTrials.gov registry entry for NCT00003775 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 45 other Brain and Central Nervous System Tumors trials with a reported enrollment target (67% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which leflunomide is the first listed.
NCT00003775 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Michigan, Ohio.
Frequently Asked Questions
What is clinical trial NCT00003775 about?
NCT00003775 is a clinical study titled "Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of leflunomide in treating patients who have anaplastic astrocytoma in first relapse.
What is the current status of trial NCT00003775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 1998-12. Estimated completion is 2006-05.
What conditions does trial NCT00003775 study?
This clinical trial studies the following conditions: Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00003775?
The interventions under investigation include: leflunomide (DRUG).
Who is sponsoring clinical trial NCT00003775?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003775 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain and Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
ACTIVE NOT RECRUITING · Phase 2
-
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
COMPLETED · Phase 2
-
Combination Chemotherapy for Patients With Brain Cancer
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma
COMPLETED · Phase 2
-
Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.